# A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

> **NCT00649207** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 80 (actual)

## Conditions studied

- Brain Diseases
- Brain Neoplasms
- Central Nervous System Diseases
- Neoplasm Metastasis
- Nervous System Neoplasms

## Interventions

- **DRUG:** ABT-888
- **RADIATION:** Whole Brain Radiation Therapy

## Key facts

- **NCT ID:** NCT00649207
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649207, "A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00649207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*